Why the study?
Foot-and-Mouth Disease remains a major global animal disease of serious economic importance, and conventional inactivated whole-virus vaccines face key limitations.
DNA vaccines represent a novel biotechnological strategy for Foot-and-Mouth Disease that can induce both humoral and cellular immunity, though large-scale field trials and delivery optimizations are still needed.
DNA vaccines may advance safer FMD control; leaves open efficacy and field translation from animal data.
This review article points out the Foot-and-Mouth Disease (FMD) as a major global animal disease of serious economic importance and limitations of conventional inactivated whole-virus vaccines. It gives DNA vaccine technology as a potential and safer way of achieving immunity by expressing microbial antigens in host cells and thereby eliciting both humoral and cellular immunity responses. The principles and mechanisms of the DNA vaccines are described in the article: antigen presentation, activation of T- T-cells, as well as the functions of adjuvants, the delivery methods, and electroporation, gene gun, and nanoparticles in the increasing of their efficacy. In addition, it summarizes the advancement in the FMD DNA vaccines against diverse viral proteins such as VP1 and the P1 polyprotein, reviews conducted experimental studies and studies in efficacy trials on animal models and the targeted livestock animal.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: